The Lancet Gastroenterology & Hepatology
Study
May 2024
Patients and professionals
A large UK-led trial of 386 newly diagnosed adults. Starting straight away with infliximab plus an immunosuppressant ('top-down') kept 79% in remission without steroids or surgery for a year, compared with 15% using the usual 'step-up' approach of trying milder drugs first. There were also fewer flares, serious side effects and operations. A blood test meant to predict who needed strong treatment did not help. Free to read in full.
Topics
Biologics and newer medicines
Research
About Crohn's disease
Jargon explained
top-down treatment
step-up treatment
biomarker
steroid-free remission
top-down
step-up
immunomodulator
randomised controlled trial
Frontline Gastroenterology (via PMC)
Guide
Nov 2025
For professionals
A readable summary of what the 2025 BSG guideline says about Crohn's. Key points: early 'top-down' infliximab with an immunomodulator for moderate to severe disease; avoiding long or repeated steroid courses; no longer suggesting immunomodulators alone; upadacitinib and risankizumab added; vedolizumab no longer routinely suggested; drug-level testing for anti-TNFs; early surgery as an option for limited ileocaecal disease; and offering early treatment after resection.
Topics
Medicines
Surgery
Monitoring
Jargon explained
top-down
step-up
therapeutic drug monitoring
ileocaecal resection
Rutgeerts score
immunogenicity
The Lancet Gastroenterology & Hepatology
Study
Nov 2026
For professionals
Five-year follow-up of the PROFILE trial. People who had early top-down treatment were less likely to be admitted to hospital or to develop strictures or fistulas than those treated step-up, with no difference seen in serious infections or cancers, suggesting early treatment may change the course of the disease.
Topics
Biologics and newer medicines
Research
Jargon explained
top-down
step-up
disease modification
stricturing
penetrating disease
ISRCTN
Tool
Patients and professionals
A WHO-recognised registry where UK and international studies are recorded before they start, with their aims and progress. You can search it free for Crohn's studies, including UK trials such as PROFILE. Records are written for researchers, so they can be technical.
Topics
Research
Jargon explained
trial registry
study protocol
ISRCTN number
Cochrane (via PMC)
Systematic review
Nov 2023
Patients and professionals
A Cochrane review finding infliximab combined with azathioprine or mercaptopurine probably works better than either thiopurine alone for bringing Crohn's into remission. Infliximab may work similarly to its CT-P13 biosimilar.
Topics
Biologics and newer medicines
Research
Jargon explained
combination therapy
purine analogue
biosimilar
CT-P13
The Lancet Gastroenterology & Hepatology
Study
Nov 2017
Patients and professionals
A Dutch and UK trial in adults whose Crohn's affected a short stretch (under 40 cm) at the end of the small bowel and had not settled with standard medicines. Keyhole surgery to remove that section was compared with infliximab, looking mainly at quality of life at one year. The authors concluded surgery is a reasonable alternative to infliximab for this group. Over about four years, 37% of the infliximab group ended up having surgery anyway.
Topics
Surgery
Biologics and newer medicines
Research
Jargon explained
laparoscopic
ileocaecal resection
terminal ileum
quality of life
terminal ileitis
ECCO and ESPGHAN (J Crohns Colitis)
Guideline
Feb 2021
For professionals
European children's gut specialists agreed how to treat Crohn's in children and teenagers. A key message is to spot early the children most likely to have a difficult course, such as those with disease around the bottom or narrowing or penetrating disease, so stronger treatment can start early and limit long-term bowel damage.
Topics
Children and young people
Medicines
Diet and nutrition
Biologics and newer medicines
Jargon explained
paediatric
penetrating disease
stricturing disease
exclusive enteral nutrition
anti-TNF
immunomodulator
therapeutic drug monitoring
New England Journal of Medicine
Study
Apr 2010
Patients and professionals
A landmark trial of 508 adults with moderate to severe Crohn's who had never had immunosuppressants or biologics. Infliximab and azathioprine together worked best: about 57% were in remission without steroids at 26 weeks, against 44% on infliximab alone and 30% on azathioprine alone. This is why many people starting infliximab are offered a second 'helper' drug alongside it.
Topics
Biologics and newer medicines
Immunosuppressants
Research
Jargon explained
combination therapy
steroid-free remission
mucosal healing
randomised controlled trial
NHS
Web page
Jul 2023
For patients
The NHS guide to depression in adults: how it differs from feeling down for a few days, common signs such as low mood and losing interest in things, when to see a GP or get urgent help, and the main treatments, including talking therapies and antidepressants.
Topics
Mental health
Jargon explained
depression
antidepressants